[
  {
    "ts": null,
    "headline": "Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst",
    "summary": "BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead",
    "url": "https://finnhub.io/api/news?id=72e3558ded082231b62edd08ccd8da4257362093ac0c732c35e6d0d3666f7f0a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734116244,
      "headline": "Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst",
      "id": 131977555,
      "image": "https://media.zenfs.com/en/Benzinga/d340fe96fb6e0ba350207d6be38ae4ff",
      "related": "RVTY",
      "source": "Yahoo",
      "summary": "BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead",
      "url": "https://finnhub.io/api/news?id=72e3558ded082231b62edd08ccd8da4257362093ac0c732c35e6d0d3666f7f0a"
    }
  }
]